Why are pharmacy acquisition costs and consumer prescription drug price indices apparently diverging?

Carolyn Wolff and Randall Lutter

Health Economics, 2020, vol. 29, issue 12, 1721-1727

Abstract: Pharmacy acquisition costs for prescription (Rx) drugs have been trending below levels implied by the Bureau of Labor Statistics' (BLS) Consumer Price Index for Rx drugs, with the divergence higher when generic approvals are high. Dropping the first 6 months of generic sales from price indices calculated from pharmacy acquisition costs eliminates most of the difference between such indices and BLS indices.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.4165

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:29:y:2020:i:12:p:1721-1727

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().